TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2683905

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 50 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB)
Number of subjects: 25
Study: 1119734

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both Alprenolol and Propranolol
Number of subjects: 107
Study: 30929458

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) training
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 113
Study: 28542874

Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg starting dose, then 80 mg every 2 weeks for 12 weeks, then 80 mg every 4 weeks)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Ustekinumab (45 mg or 90 mg weight-based dosing)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 302

Group type: COMPARATOR
Intervention: Ixekizumab and Ustekinumab
Number of subjects: 302
Study: 25145882

Group type: EXPERIMENTAL
Intervention: Shoe inserts and high-load progressive strength training (unilateral heel raises with a towel under the toes), performed every second day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Shoe inserts and daily plantar-specific stretching
Number of subjects: 48
Study: 23715903

Group type: EXPERIMENTAL
Intervention: FDG PET performed on day 21 of chemoradiotherapy (4.5 MBq/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: FDG PET performed before chemoradiotherapy (PET₁)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: FDG PET performed on day 21 of chemoradiotherapy (PET₂)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Changes in SUVmax, TV₄₀, TVp, TLG₄₀ and TLGp between PET₁ and PET₂
Number of subjects: 57
Study: 22273215

Group type: EXPERIMENTAL
Intervention: Modified double tracks anastomosis
Number of subjects: 396

Group type: COMPARATOR
Intervention: Esophagus‐remnant stomach direct anastomosis
Number of subjects: 396
Study: 19230959

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 microg twice daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 17335297

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5mg
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: ivabradine 10mg
Number of subjects: 1195

Group type: COMPARATOR
Intervention: amlodipine 10mg
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5mg and 10mg
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: ivabradine and amlodipine
Number of subjects: 1195

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 1195
Study: 15350853

Group type: EXPERIMENTAL
Intervention: Exposure in vivo (E; n = 25)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT; n = 26)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait‐list control (WLC; n = 22)
Number of subjects: 73
Study: 16400502

Group type: EXPERIMENTAL
Intervention: Teeth brushing education for two years
Number of subjects: 292

Group type: COMPARATOR
Intervention: No teeth brushing education (Control)
Number of subjects: 292
Study: 10342086

Group type: EXPERIMENTAL
Intervention: Vaginal ring with 3 mm thickness
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vaginal ring with 3.5 mm thickness
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vaginal ring with 4 mm thickness
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall experience with the vaginal rings
Number of subjects: 65
Study: 8726925

Group type: EXPERIMENTAL
Intervention: 15 mg 16 h nicotine patches (LC‐15)
Number of subjects: 297

Group type: COMPARATOR
Intervention: 25 mg 16 h nicotine patches (HC‐25)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 15 mg 16 h nicotine patches (HC‐15)
Number of subjects: 297
Study: 1822264

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day)
Number of subjects: 8
Study: 6124653

Group type: EXPERIMENTAL
Intervention: Beta‐1‐adrenergic blockade (100 mg metoprolol)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (unmedicated condition)
Number of subjects: 14
Study: 30810533

Group type: EXPERIMENTAL
Intervention: MotivATE (Web-based intervention)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: MotivATE (registered users)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 313
Study: 29470854

Group type: EXPERIMENTAL
Intervention: Screening program using the FRAX® risk assessment tool and bone mineral density (BMD) measures
Number of subjects: 12483

Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 12483

Group type: COMPARATOR
Intervention: Usual management (control)
Number of subjects: 12483
Study: 26409713

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 59
Study: 24690470

Group type: EXPERIMENTAL
Intervention: 15-session school-based intervention implemented by para-professionals
Number of subjects: 329

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 329
Study: 23147978

Group type: EXPERIMENTAL
Intervention: Massage therapy (MT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham therapy (control)
Number of subjects: 120
Study: 19573262

Group type: EXPERIMENTAL
Intervention: Reattribution training (RT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 141
Study: 17631786

Group type: EXPERIMENTAL
Intervention: Topical adelmidrol 2% emulsion applied twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (6 patches in 6 subjects with multiple lesions that had not been treated)
Number of subjects: 20
Study: 16140229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11836291

Group type: EXPERIMENTAL
Intervention: Leuprolide 3‐month depot 22.5 mg im every 12 wk for 48 wk
Number of subjects: 40
Study: 10761536

Group type: EXPERIMENTAL
Intervention: Combination regimen of mefloquine (750 mg) and quinine (600 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Quinine sulfate (600 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Mefloquine (750 mg) alone
Number of subjects: 7
Study: 7745336

Group type: EXPERIMENTAL
Intervention: Electrodissection technique
Number of subjects: 104

Group type: COMPARATOR
Intervention: Blunt dissection and ligation technique
Number of subjects: 104
Study: 31914242

Group type: EXPERIMENTAL
Intervention: Coalition's care‐transition program
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study: 31028165

Group type: EXPERIMENTAL
Intervention: 18F‐PSMA‐11 administered at 2 MBq per kilogram of body weight
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 18F‐PSMA‐11
Number of subjects: 6
Study: 28504321

Group type: EXPERIMENTAL
Intervention: 0.25% intranasal phenylephrine (Group 2)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 0.5% intranasal phenylephrine (Group 3)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intranasal saline (Group 1)
Number of subjects: 77
Study: 25343233

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg infusions, two doses 2 weeks apart
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline infusions), two doses 2 weeks apart
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study: 24652170

Group type: EXPERIMENTAL
Intervention: Iron amino acid chelate (12.5 mg of iron in 13 g of milk)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ferrous sulfate (12.5 mg of iron in 13 g of milk)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Iron amino acid chelate
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study: 21355144

Group type: EXPERIMENTAL
Intervention: Acupoint group (moxibustion at Sanyinjiao SP 6)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Non-acupoint group
Number of subjects: 174

Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 174
Study: 19787753

Group type: EXPERIMENTAL
Intervention: Silver-donating antimicrobial dressings
Number of subjects: 213

Group type: COMPARATOR
Intervention: Non-silver low-adherence dressings (Control)
Number of subjects: 213
Study: 16942571

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 6750

Group type: COMPARATOR
Intervention: Drugs only (Control)
Number of subjects: 6750

Group type: EXPERIMENTAL
Intervention: Mites
Number of subjects: 6750

Group type: EXPERIMENTAL
Intervention: Birch
Number of subjects: 6750

Group type: EXPERIMENTAL
Intervention: Grasses
Number of subjects: 6750

Group type: EXPERIMENTAL
Intervention: Parietaria
Number of subjects: 6750
Study: 15233975

Group type: COMPARATOR
Intervention: Prehypertensive individuals (653 men, 535 women)
Number of subjects: 3042
Study: 11508024

Group type: EXPERIMENTAL
Intervention: Sound of the dentist's drill
Number of subjects: 42

Group type: COMPARATOR
Intervention: No sound of the dentist's drill
Number of subjects: 42
Study: 9237960

Group type: EXPERIMENTAL
Intervention: 18 g/d olestra
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 18 g/d olestra plus 1.1 mg tocopheryl acetate/g olestra
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (18 g/d triglyceride)
Number of subjects: 100
Study: 8513842

Group type: EXPERIMENTAL
Intervention: 90 mg codeine
Number of subjects: 25

Group type: COMPARATOR
Intervention: 45 mg codeine
Number of subjects: 25
Study: 2880688

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.025 to 1.0 microgram/kg/min for 2 hours)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.50 microgram/kg/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoldopam (doses greater than 0.25 microgram/kg/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fenoldopam
Number of subjects: 18
Study: 31650711

Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg 3 times a day (days 16-28) with carbamazepine 100 mg twice a day (days 1-3) and 200 mg twice a day (days 4-21)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg 3 times a day (days 16-28) after carbamazepine discontinuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine with vixotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31609706

Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conservative management (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moderate pyelectasis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Severe RPD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pathologic scintigraphies
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High creatinine levels (>0.6 mg/dl)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Monolateral irreversible renal function impairment
Number of subjects: 90
Study: 28678950

Group type: EXPERIMENTAL
Intervention: 1% sodium alendronate (ALN) gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25733460

Group type: EXPERIMENTAL
Intervention: Dairy products (474 mL/d 2% milk and 170 g/d low-fat yogurt)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sugar-sweetened products (710 mL/d nondiet soda and 108 g/d nondairy pudding)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sugar-sweetened products
Number of subjects: 100
Study: 23932217

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 13
Study: 21258823

Group type: EXPERIMENTAL
Intervention: Multimodal therapy including cognitive-behavioral therapy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study: 19592602

Group type: EXPERIMENTAL
Intervention: Conventional cigarette (CC, tar: 11 mg, Nic: 0.8 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS: tar: 5 mg, Nic: 0.3 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No smoking (NS)
Number of subjects: 30
Study: 16415300

Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors with GuardWire embolic protection
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors with FilterWire embolic protection
Number of subjects: 651

Group type: COMPARATOR
Intervention: FilterWire embolic protection without IIb/IIIa inhibitors
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors
Number of subjects: 651
Study: 14728071

Group type: EXPERIMENTAL
Intervention: Losartan 50‐100 mg/day
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol 50‐100 mg/day
Number of subjects: 9193
Study: 10619950

Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study: 9176466

Group type: EXPERIMENTAL
Intervention: Transcervical GIFT using a linear everting catheter with direct falloposcopic vision
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcervical GIFT using a linear everting catheter
Number of subjects: 25
Study: 1492270

Group type: EXPERIMENTAL
Intervention: Topical application of drug cream (papaverine and phentolamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical treatment
Number of subjects: 0
Study: 3754572

Group type: EXPERIMENTAL
Intervention: Patients less than 35 years of age
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Patients 36 to 45 years of age
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Patients greater than 45 years of age
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Patients with better performance status, less than three sites of metastases, and without visceral or nodal metastases
Number of subjects: 1168
Study: 29766325

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Group (MIG)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional Intervention Group (CIG)
Number of subjects: 83
Study: 27234605

Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 52

Group type: COMPARATOR
Intervention: No rubber dam
Number of subjects: 52
Study: 25156780

Group type: EXPERIMENTAL
Intervention: 3.0% BCAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA supplementation in patients
Number of subjects: 0
Study: 22846159

Group type: EXPERIMENTAL
Intervention: memantine (titrated up by 5 mg week⁻¹ to 20 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 21226877

Group type: EXPERIMENTAL
Intervention: Yomogi AGEs Clearing (YAC) extract
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo product without an anti-aging substance
Number of subjects: 91
Study: 18657175

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 16485750

Group type: EXPERIMENTAL
Intervention: Lipschitz exponent (LE) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interscale wavelet maximum (ISWM) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Turns Analysis (TA) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of the mean LE value to the number of singular points
Number of subjects: 0
Study: 15370682

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11535316

Group type: COMPARATOR
Intervention: Live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine, administered orally with childhood vaccines at 2, 4, and 6 months of age
Number of subjects: 20

Group type: COMPARATOR
Intervention: Live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9692077

Group type: EXPERIMENTAL
Intervention: Intermittent monofluorophosphate 114 mg/day plus continuous calcium supplementation (950-1000 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Continuous calcium (1000 mg/day) alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intermittent monofluorophosphate plus calcium
Number of subjects: 64

Group type: COMPARATOR
Intervention: Continuous calcium alone
Number of subjects: 64
Study: 7848337

Group type: EXPERIMENTAL
Intervention: Theophyllard (test preparation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 24
Study: 2525943

Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg, twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naproxen (500 mg, twice daily)
Number of subjects: 30
Study: 31612201

Group type: EXPERIMENTAL
Intervention: Highest quintile of serum retinol
Number of subjects: 29104
Study: 30097133

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) treatment and clinical monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clinical monitoring only
Number of subjects: 60
Study: 26058477

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 24042479

Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: No placebo
Number of subjects: 0
Study: 23425731

Group type: EXPERIMENTAL
Intervention: Tube thoracostomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 90
Study: 20610947

Group type: EXPERIMENTAL
Intervention: Street children experiencing harassment or abuse
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Drug use among street children
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Sexual activity among older adolescents (15-17 years)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Multiple sexual partners among sexually active adolescents (15-17 years)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Condom use among sexually active adolescents (15-17 years)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Sexual abuse among girls
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Overlap with high-risk populations for HIV
Number of subjects: 857
Study: 17468035

Group type: EXPERIMENTAL
Intervention: Submental approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submandibular approach
Number of subjects: 20
Study: 16801296

Group type: EXPERIMENTAL
Intervention: Nicotine spray (active)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Deprivation (12‐hr deprived)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Nondeprived
Number of subjects: 115
Study: 14653293

Group type: EXPERIMENTAL
Intervention: Filtek Flow with manufacturer's dentin adhesive (Single Bond)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dyract Flow with manufacturer's dentin adhesive (Prime & Bond NT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Admira Flow with manufacturer's dentin adhesive (Admira Bond)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Filtek Flow with different brand dentin adhesive (Gluma Comfort Bond)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dyract Flow with different brand dentin adhesive (Gluma Comfort Bond)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Admira Flow with different brand dentin adhesive (Gluma Comfort Bond)
Number of subjects: 48
Study: 11037993

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite grafts
Number of subjects: 12

Group type: COMPARATOR
Intervention: Iliac bone autografts
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (HA grafts and autografts)
Number of subjects: 12
Study: 8831304

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 21
Study: 1466325

Group type: EXPERIMENTAL
Intervention: nicardipine-SR 45 mg twice daily
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: nicardipine-SR 60 mg twice daily
Number of subjects: 218

Group type: COMPARATOR
Intervention: verapamil-SR 240 mg once daily
Number of subjects: 218
Study: 3970798

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate-neostigmine mixture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atropine-neostigmine mixture
Number of subjects: 50
Study: 30963443

Group type: EXPERIMENTAL
Intervention: e-cigarette aerosol with nicotine
Number of subjects: 17

Group type: COMPARATOR
Intervention: e-cigarette aerosol without nicotine
Number of subjects: 17
Study: 29538220

Group type: EXPERIMENTAL
Intervention: Chinese medicine warm compress (CMWC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: WHO 3-step analgesic ladder treatment
Number of subjects: 62
Study: 30640989

Group type: EXPERIMENTAL
Intervention: Conventional care plus acupoint massage (Zusanli (ST36), Shangjuxu (ST37), Liangqiu (ST34), Yinshi (ST33), Futo (ST32))
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional care plus intermittent limb pressure treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Test group (acupoint massage)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (intermittent limb pressure treatment)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 106
Study: 24668714

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) added to 30 ml 0.25% levobupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Levobupivacaine (30 ml 0.25%) with 2 ml 0.9% NaCl
Number of subjects: 42
Study: 23415776

Group type: COMPARATOR
Intervention: Combination therapy (fortified cefazolin sodium 5% and tobramycin sulfate 1.3%)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Monotherapy (moxifloxacin 0.5%)
Number of subjects: 224
Study: 20856180

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 50
Study: 18212034

Group type: EXPERIMENTAL
Intervention: 10-week cardiac rehabilitation programme (16 cycle ergometry sessions and 2 stress-management classes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (excluding aerobic exercise)
Number of subjects: 48
Study: 15818702

Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib
Number of subjects: 387

Group type: COMPARATOR
Intervention: Naproxen 1000 mg
Number of subjects: 387